. Antibiotic susceptibility of the MBL-producing isolates 
P. aeruginosa M-120 (IMP) <1 (S) 128/64 (R) 2 (R) 16 (R) 4 (R) 1 (S)
a R: resistant; S: sensitive. Sensitivity to the tested antibiotics (except for cefoperazone) according to the clinical MIC breakpoints issued by the European Committee on Antimicrobial Susceptibility Testing (EUCAST). 9 For cefoperazone, the MIC breakpoint based on that published by the United States food and drug administration (FDA).
10
b MIC data provided by Utrecht University medical center. 
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